Avoid Switching Methadone Products in Patients With Opioid Use Disorder

June 2020

Health Canada is warning about the risk of withdrawal symptoms when switching methadone formulations in patients with opioid use disorder.

This is based on case reports of patients having withdrawal symptoms after switching between methadone liquids...Metadol-D, Methadose, and Sandoz-methadone...even after being stable for years.

The concern is that some patients may experience withdrawal symptoms...and turn to street drugs to alleviate cravings OR quit their treatment program altogether.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Subscription Options

Already a subscriber? Log in

Volume pricing available. Get quote

Immunizations Keep Immunizations on Track During COVID-19
Infectious Diseases Put Treatments for COVID-19 in Perspective
Diabetes Temper Buzz About the First Oral GLP-1 Agonist, Rybelsus
Dermatology Manage Skin Irritation Due to Handwashing and PPE
Infectious Diseases Settle Debate About Vancomycin or Fidaxomicin for C. diff
Opioids Avoid Switching Methadone Products in Patients With Opioid Use Disorder
Communication Enhance Your Telecommunication Skills
Anticoagulants Expect to See DOACs for Venous Thromboembolism Due to Cancer
Practice Weigh the Situation When Patients Ask About Expiration Dates
Poison Prevention Provide Strategies to Prevent Poisonings

Avoid Switching Methadone Products in Patients With Opioid Use Disorder

Get concise advice on drug therapy, plus unlimited access to CE

Table of Contents